About Myeloid differentiation primary response protein MyD88
Myeloid differentiation primary response protein MyD88 (MYD88) is a protein
from Homo sapiens identified by UniProt accession
Q99836, 296 residues long.
MolForge cross-references it against 0 known binders and
1,055 disease associations.
Target properties
| Protein name | Myeloid differentiation primary response protein MyD88 |
|---|
| UniProt accession | Q99836 |
|---|
| Gene | MYD88 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 296 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (1055)
Diseases linked to this target (Open Targets).
- pyogenic bacterial infections due to MyD88 deficiency · score 0.73
- chronic lymphocytic leukemia · score 0.71
- diffuse large B-cell lymphoma · score 0.65
- lymphoid leukemia · score 0.52
- inborn error of immunity · score 0.51
- lymphocyte count · score 0.46
- lymphocyte percentage of leukocytes · score 0.46
- neutrophil percentage of leukocytes · score 0.44
- non-Hodgkins lymphoma · score 0.44
- lymphoma · score 0.42
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q99836-F1 | alphafold | PREDICTED | 80.56 | — |
Amino-acid sequence (296 residues)
MAAGGPGAGS AAPVSSTSSL PLAALNMRVR RRLSLFLNVR TQVAADWTAL AEEMDFEYLE IRQLETQADP TGRLLDAWQG RPGASVGRLL ELLTKLGRDD VLLELGPSIE EDCQKYILKQ QQEEAEKPLQ VAAVDSSVPR TAELAGITTL DDPLGHMPER FDAFICYCPS DIQFVQEMIR QLEQTNYRLK LCVSDRDVLP GTCVWSIASE LIEKRCRRMV VVVSDDYLQS KECDFQTKFA LSLSPGAHQK RLIPIKYKAM KKEFPSILRF ITVCDYTNPC TKSWFWTRLA KALSLP
Explore Myeloid differentiation primary response protein MyD88 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets